The acute inflammatory response to intranigral α-synuclein differs significantly from intranigral lipopolysaccharide and is exacerbated by peripheral inflammation

Journal of Neuroinflammation

Daniel C Anthony¹  Matthew JA Wood⁴  Nicola R Sibson³  Lydia Alvarez-Erviti²  Yvonne Couch¹ 

[1] Experimental Neuropathology, Department of Pharmacology, University of Oxford, Oxford, OX1 3QT, UK;Department of Clinical Neuroscience, UCL Institute of Neurology, London, NW3 2PF, UK;Gray Institute for Radiation Oncology and Biology, Department of Oncology, University of Oxford Radiobiology Research Institute, Churchill Hospital, Oxford, OX3 7LJ, UK;Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, OX1 3QX, UK

关键词: chemokine;    Parkinson's;    cytokine;    SNCA;    α-synuclein;    inflammation;    brain;   

Others  :  1212985
DOI  :  10.1186/1742-2094-8-166

 received in 2011-06-09, accepted in 2011-11-28,  发布年份 2011

【 摘 要 】

Background

Activated microglia are a feature of the host response to neurodegeneration in Parkinson's disease (PD) and are thought to contribute to disease progression. Recent evidence suggests that extracellular α-synuclein (eSNCA) may play an important role in the pathogenesis of PD and that this may be mediated by a microglial response.

Methods

We wished to discover whether the host response to eSNCA would be sufficient to induce significant cytokine production. In vitro cultured BV-2 microglia were used to determine the basic inflammatory response to eSNCA. In vivo, 8-week old Biozzi mice were subjected to a single intranigral injection of either 3 μg SNCA, lipopolysaccharide (LPS) or serum protein (BSA) and allowed to recover for 24 hours. A second cohort of animals were peripherally challenged with LPS (0.5 mg/kg) 6 hours prior to tissue collection. Inflammation was studied by quantitative real-time PCR for a number of pro-inflammatory genes and immunohistochemistry for microglial activation, endothelial activation and cell death.

Results

In vitro data showed a robust microglial response to SNCA, including a positive NFĸB response and the production of pro-inflammatory cytokines. Direct injection of SNCA into the substantia nigra resulted in the upregulation of mRNA expression of proinflammatory cytokines, the expression of endothelial markers of inflammation and microglial activation. However, these results were significantly different to those obtained after direct injection of LPS. By contrast, when the animals were injected intracerebrally with SNCA and subsequently challenged with systemic LPS, the level of production of IL-1β in the substantia nigra became comparable to that induced by the direct injection of LPS into the brain. The injection of albumin into the nigra with a peripheral LPS challenge did not provoke the production of a significant inflammatory response. Direct injection of LPS into the substantia nigra also induces cell death in a more robust manner than direct injection of either SNCA or BSA.

Conclusion

These results suggest that the presence of eSNCA protein 'primes' microglia, making them susceptible to environmental proinflammatory challenge. For this reason, we hypothesise that where 'inflammation' contributes to the disease progression in PD, it does so in a punctuate manner (on-off) as a result of systemic events.

【 授权许可】

   
2011 Couch et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Figure 8.

【 参考文献 】

• [1]Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M: alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proceedings of the National Academy of Sciences of the United States of America 1998, 95:6469-6473.
• [2]Li JY, Englund E, Holton JL, Soulet D, Hagell P, Lees AJ, Lashley T, Quinn NP, Rehncrona S, Bjorklund A, et al.: Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med 2008, 14:501-503.
• [3]Lee HJ, Patel S, Lee SJ: Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. J Neurosci 2005, 25:6016-6024.
• [4]Klegeris A, Giasson BI, Zhang H, Maguire J, Pelech S, McGeer PL: Alpha-synuclein and its disease-causing mutants induce ICAM-1 and IL-6 in human astrocytes and astrocytoma cells. Faseb J 2006, 20:2000-2008.
• [5]Zhang W, Wang T, Pei Z, Miller DS, Wu X, Block ML, Wilson B, Zhang W, Zhou Y, Hong JS, Zhang J: Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. Faseb J 2005, 19:533-542.
• [6]Hyde SC, Pringle IA, Abdullah S, Lawton AE, Davies LA, Varathalingam A, Nunez-Alonso G, Green AM, Bazzani RP, Sumner-Jones SG, et al.: CpG-free plasmids confer reduced inflammation and sustained pulmonary gene expression. Nature biotechnology 2008, 26:549-551.
• [7]Blum-Degen D, Muller T, Kuhn W, Gerlach M, Przuntek H, Riederer P: Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neuroscience letters 1995, 202:17-20.
• [8]Mogi M, Harada M, Riederer P, Narabayashi H, Fujita K, Nagatsu T: Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neuroscience letters 1994, 165:208-210.
• [9]Nagatsu T: Isoquinoline neurotoxins in the brain and Parkinson's disease. Neuroscience research 1997, 29:99-111.
• [10]Qin L, Wu X, Block ML, Liu Y, Breese GR, Hong JS, Knapp DJ, Crews FT: Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia 2007, 55:453-462.
• [11]Castano A, Herrera AJ, Cano J, Machado A: The degenerative effect of a single intranigral injection of LPS on the dopaminergic system is prevented by dexamethasone, and not mimicked by rh-TNF-alpha, IL-1beta and IFN-gamma. J Neurochem 2002, 81:150-157.
• [12]Ariza D, Lima MM, Moreira CG, Dombrowski PA, Avila TV, Allemand A, Mendes DA, Da Cunha C, Vital MA: Intranigral LPS administration produces dopamine, glutathione but not behavioral impairment in comparison to MPTP and 6-OHDA neurotoxin models of Parkinson's disease. Neurochem Res 2010, 35:1620-1627.
• [13]Paxinos G, Franklin KBJ: The mouse brain in stereotaxic coordinates. Academic Press; 2004.
• [14]Campbell SJ, Perry VH, Pitossi FJ, Butchart AG, Chertoff M, Waters S, Dempster R, Anthony DC: Central Nervous System Injury Triggers Hepatic CC and CXC Chemokine Expression that Is Associated with Leukocyte Mobilization and Recruitment to Both the Central Nervous System and the Liver. Am J Pathol 2005, 166:1487-1497.
• [15]Warnke R, Levy R: Detection of T and B cell antigens hybridoma monoclonal antibodies: a biotin-avidin-horseradish peroxidase method. J Histochem Cytochem 1980, 28:771-776.
• [16]Nakashima Y, Sun DH, Trindade MC, Maloney WJ, Goodman SB, Schurman DJ, Smith RL: Signaling pathways for tumor necrosis factor-alpha and interleukin-6 expression in human macrophages exposed to titanium-alloy particulate debris in vitro. The Journal of bone and joint surgery 1999, 81:603-615.
• [17]Reynolds AD, Kadiu I, Garg SK, Glanzer JG, Nordgren T, Ciborowski P, Banerjee R, Gendelman HE: Nitrated alpha-synuclein and microglial neuroregulatory activities. J Neuroimmune Pharmacol 2008, 3:59-74.
• [18]Bateman RJ, Munsell LY, Morris JC, Swarm R, Yarasheski KE, Holtzman DM: Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med 2006, 12:856-861.
• [19]Varadarajan S, Kanski J, Aksenova M, Lauderback C, Butterfield DA: Different mechanisms of oxidative stress and neurotoxicity for Alzheimer's A beta(1--42) and A beta(25--35). Journal of the American Chemical Society 2001, 123:5625-5631.
• [20]Bonaiuto C, McDonald PP, Rossi F, Cassatella MA: Activation of nuclear factor-kappa B by beta-amyloid peptides and interferon-gamma in murine microglia. Journal of neuroimmunology 1997, 77:51-56.
• [21]Meda L, Baron P, Prat E, Scarpini E, Scarlato G, Cassatella MA, Rossi F: Proinflammatory profile of cytokine production by human monocytes and murine microglia stimulated with beta-amyloid[25-35]. J Neuroimmunol 1999, 93:45-52.
• [22]Smits HA, van Beelen AJ, de Vos NM, Rijsmus A, van der Bruggen T, Verhoef J, van Muiswinkel FL, Nottet HS: Activation of human macrophages by amyloid-beta is attenuated by astrocytes. J Immunol 2001, 166:6869-6876.
• [23]Reynolds AD, Stone DK, Mosley RL, Gendelman HE: Nitrated {alpha}-synuclein-induced alterations in microglial immunity are regulated by CD4+ T cell subsets. J Immunol 2009, 182:4137-4149.
• [24]Lewin SR, Lambert P, Deacon NJ, Mills J, Crowe SM: Constitutive expression of p50 homodimer in freshly isolated human monocytes decreases with in vitro and in vivo differentiation: a possible mechanism influencing human immunodeficiency virus replication in monocytes and mature macrophages. J Virol 1997, 71:2114-2119.
• [25]Su X, Federoff HJ, Maguire-Zeiss KA: Mutant alpha-synuclein overexpression mediates early proinflammatory activity. Neurotox Res 2009, 16:238-254.
• [26]Campbell SJ, Carare-Nnadi RO, Losey PH, Anthony DC: Loss of the atypical inflammatory response in juvenile and aged rats. Neuropathol Appl Neurobiol 2007, 33:108-120.
• [27]Villaran RF, Espinosa-Oliva AM, Sarmiento M, de Pablos RM, Arguelles S, Delgado-Cortes MJ, Sobrino V, van Rooijen N, Venero JL, Herrera AJ, et al.: Ulcerative Colitis Exacerbates Lps-Induced Damage to the Nigral Dopaminergic System: Potential Risk Factor in Parkinson;S Disease. J Neurochem 2010.
• [28]Pohlers D, Siegling A, Buchner E, Schmidt-Weber CB, Palombo-Kinne E, Emmrich F, Brauer R, Kinne RW: Expression of cytokine mRNA and protein in joints and lymphoid organs during the course of rat antigen-induced arthritis. Arthritis research & therapy 2005, 7:R445-457. BioMed Central Full Text
• [29]Walsh DT, Betmouni S, Perry VH: Absence of detectable IL-1beta production in murine prion disease: a model of chronic neurodegeneration. J Neuropathol Exp Neurol 2001, 60:173-182.
• [30]Blond D, Campbell SJ, Butchart AG, Perry VH, Anthony DC: Differential induction of interleukin-1beta and tumour necrosis factor-alpha may account for specific patterns of leukocyte recruitment in the brain. Brain Res 2002, 958:89-99.
• [31]Lumsden C: The neuropathology of multiple sclerosis. In Handbook of Clinical Neurology. Multiple sclerosis and other demyelinating diseases. Volume 9. Edited by Vinken PJ, Bruyn GW. Amsterdam: Elsevier; 1970::217-309.
• [32]Cunningham C, Boche D, Perry VH: Transforming growth factor beta1, the dominant cytokine in murine prion disease: influence on inflammatory cytokine synthesis and alteration of vascular extracellular matrix. Neuropathol Appl Neurobiol 2002, 28:107-119.
• [33]Walsh DT, Perry VH, Minghetti L: Cyclooxygenase-2 is highly expressed in microglial-like cells in a murine model of prion disease. Glia 2000, 29:392-396.
• [34]Tomoda T, Shirasawa T, Yahagi YI, Ishii K, Takagi H, Furiya Y, Arai KI, Mori H, Muramatsu MA: Transforming growth factor-beta is a survival factor for neonate cortical neurons: coincident expression of type I receptors in developing cerebral cortices. Dev Biol 1996, 179:79-90.
• [35]Butovsky O, Talpalar AE, Ben-Yaakov K, Schwartz M: Activation of microglia by aggregated beta-amyloid or lipopolysaccharide impairs MHC-II expression and renders them cytotoxic whereas IFN-gamma and IL-4 render them protective. Molecular and cellular neurosciences 2005, 29:381-393.
• [36]Gao HM, Zhang F, Zhou H, Kam W, Wilson B, Hong JS: Neuroinflammation and alpha-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson's disease. Environ Health Perspect 2011, 119:807-814.
• [37]Nieto M, Gil-Bea FJ, Dalfo E, Cuadrado M, Cabodevilla F, Sanchez B, Catena S, Sesma T, Ribe E, Ferrer I, et al.: Increased sensitivity to MPTP in human alpha-synuclein A30P transgenic mice. Neurobiol Aging 2006, 27:848-856.
• [38]Norris EH, Uryu K, Leight S, Giasson BI, Trojanowski JQ, Lee VM: Pesticide exposure exacerbates alpha-synucleinopathy in an A53T transgenic mouse model. Am J Pathol 2007, 170:658-666.
• [39]Serres S, Anthony DC, Jiang Y, Broom KA, Campbell SJ, Tyler DJ, van Kasteren SI, Davis BG, Sibson NR: Systemic inflammatory response reactivates immune-mediated lesions in rat brain. J Neurosci 2009, 29:4820-4828.
• [40]Cunningham C, Wilcockson DC, Campion S, Lunnon K, Perry VH: Central and systemic endotoxin challenges exacerbate the local inflammatory response and increase neuronal death during chronic neurodegeneration. J Neurosci 2005, 25:9275-9284.
• [41]McColl BW, Rothwell NJ, Allan SM: Systemic inflammatory stimulus potentiates the acute phase and CXC chemokine responses to experimental stroke and exacerbates brain damage via interleukin-1- and neutrophil-dependent mechanisms. J Neurosci 2007, 27:4403-4412.
• [42]Godoy MC, Tarelli R, Ferrari CC, Sarchi MI, Pitossi FJ: Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson's disease. Brain 2008, 131:1880-1894.
• [43]Giovannoni G, Ebers G: Multiple sclerosis: the environment and causation. Curr Opin Neurol 2007, 20:261-268.
• [44]Dobbs RJ, Dobbs SM, Weller C, Charlett A, Bjarnason IT, Curry A, Ellis DS, Ibrahim MA, McCrossan MV, O'Donohue J, et al.: Helicobacter hypothesis for idiopathic parkinsonism: before and beyond. Helicobacter 2008, 13:309-322.